The immunosuppressant fingolimod ameliorates experimental autoimmune myasthenia gravis by regulating T-cell balance and cytokine secretion.

In conclusion, our results suggest that fingolimod has a preventive effect on experimental autoimmune myasthenia gravis by interfering with lymphocyte function. PMID: 32655793 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/32655793?dopt=Abstract

Source: American Journal of Translational Research - July 15, 2020 Category: Research Tags: Am J Transl Res Source Type: research